UMBERTO MANERA
MD, Neurologist, Research Fellow, PhD student

PERSONAL INFORMATION
Researcher unique identifier (ORCID): 0000-0002-9995-8133
Year of birth: 1987 Nationality: Italian
Institutional web site: https://www.neuroscienze.unito.it/do/docenti.pl/Show?_id=umanera
Email: umberto.manera@unito.it

EDUCATION AND TRAINING
2018-ongoing PhD Program in Neuroscience – University of Turin, Italy
2013-2018 Neurology Residency – School of Medicine and Surgery, University of Turin, Italy
2006-2012 MD - School of Medicine and Surgery, University of Turin, Italy

CURRENT POSITIONS
2021- current Research Fellow in Neurology, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Italy
2021- current Neurologist at 'Città della Salute e della Scienza' University Hospital, Neurology 1 Division, Turin, Italy

PREVIOUS POSITIONS
2018-2021 Consultant neurologist for the Neurology Unit at Koelliker Hospital, Turin
2012-2013 Research Grant 'Training in Neuroimaging Techniques in ALS' 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Italy
2010-2012 Monitor for the Piedmont Region in the Study of the possible association between H1N1 vaccination and Guillain-Barré syndrome onset, Research Grant 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Italy

FELLOWSHIPS AND AWARDS
2019 First prize PriSLA Awards 2018/2019
2016 Poster prize selection "The Spreading Of Symptoms At Diagnosis In ALS Is A Marker Of Prognosis: A Population-Based Study" - 27th International Symposium on ALS/MND, Dublin

REVIEWING ACTIVITY
I am a reviewer for several international neuroscience and genetic journals, including Annals of Neurology, Cells (MDPI), PLOS ONE, Disability and Rehabilitation, Frontiers in Neurology (Research Topic Editor)

MEMBERSHIPS OF SCIENTIFIC SOCIETIES / ACADEMIES / RESEARCH CONSORTIA
2020 Member of *SINDEM (Associazione Autonoma per le Demenze Aderente alla Sin)*
2018 Member of *TRICALS(Treatment Research Initiative to Cure ALS)*
2018 Member of the *AAN (American Academy of Neurology)*
2018 Member of *AIP (Associazione Italiana di Psicogeriatria)*
2017 Associate Member of *EAN (European Academy of Neurology)*
2015 Member of the *Italian ALS Genetic* (ITALSGEN) consortium
2014 Member of the *Italian MND research group*
2014 Member of *ENCALS* (*European Network for the Cure of ALS)*

2013 Member of the *Euro-MOTOR Consortium (European multidisciplinary ALS network identification to cure motor neuron degeneration)*
2013 Member of *SIN (Società Italiana di Neurologia)*
2011 Member of *PARALS (Piedmont and Valle d'Aosta Register for Amyotrophic Lateral Sclerosis)*

CLINICAL TRIALS
Since 2013, I have been study Investigator in the following multicenter randomized clinical trials:

- 233AS101: *A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation*
- 233AS102: *An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation*
- ORARIALS-01: *A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis*
- ORARIALS-02 : *Open-label, Non-randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol Citrate 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS) who have Completed the ORARIALS-01 Trial*
- RAP-ALS: *Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis*
- REFALS: *Effects of oral levosimendan (ODM-109) on respiratory function in patients with ALS*
- REFALS-ES: *Effects of oral levosimendan (ODM-109) on respiratory function in patients with ALS: open-label extension for patients completing study 3119002*
- TUDCA-ALS: *Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)*
- ALXN-1210-308: *A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)*
- SOD1-ITALS: *SOD1 in Italian ALS Patients: A National Survey*
- MT-1186-A01: *A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)*
- MT-1186-A02: *A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)*
- MT-1186-A03: *A Phase 3, Multi-Center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)*
- AB19001: *A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole versus placebo in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)*

SCIENTIFIC EXPERIENCE
My current work focuses on building new strategies to untangle the complexity of amyotrophic lateral sclerosis - frontotemporal dementia using modern genetic, imaging, and machine learning approaches, the development of novel biomarkers, and the discovery of more effective drugs to improve symptoms and slow disease progression.
Since 2013, I have been study Investigator in the following observational studies:

- BONE-ALS: *Dual-Energy X-Ray Absorptiometry (Dexa) As A Marker Of Previous Physical Activity As Phenotype Determinant In ALS Patients*

- BRAIN-MEND: *Biological Resource Analysis to Identify New MEchanisms and phenotypes in Neurodegenerative Diseases*
- INITIALS: *Identification of geNetic and envIronmental deTermInants of onset and progression of ALS*
- PARALS: *Retrospective study of the natural history and genetic subtypes of ALS patients in the PARALS registry in Italy*
- REVEALS: *Registry of endpoints and validated experiences in ALS*
- GR-2019-12371291: *Multimodal magnetic resonance imaging in a large sample of ALS patients: identification of clinical phenotypes and prediction of disease progression*
- RF_2018_12365614: *TDP-43 pathology and Lys-acetylation in circulating lymphomonocytes as biomarkers and therapeutic hints for amyotrophic lateral sclerosis*
- BIO-SLA: *Diagnostic And Prognostic Biomarkers Research In Patients With Motor Neuron Diseases*
- IT-ALS-11841: *Retrospective study of the natural history and genetic subtypes of ALS patients in the PARALS registry in Italy*

TEACHING EXPERIENCE

- Teaching assistant in Neurology, Undergraduate degree in Speech and Language Therapy, a.y. 2020/2021, University of Turin
- Teaching assistant in Neurology and Neurorehabilitation - Clinical nursing in chronic care disability and palliative care, Undergraduate degree in Nursing, a.y. 2020/2021, University of Turin
- Teaching assistant in Neurology, Graduate degree in Medicine and Surgery, a.y. 2018/2019 and 2019/2020, San Luigi Gonzaga Hospital, University of Turin
- Training course for Social Workers and Caregivers for the Valle d'Aosta Region – Project AISLA 2017

BIBLIOMETRIC DATA

Full text papers in peer-reviewed journals: 81
H-index: 21 (Scopus)
Total number of citations: 1644 (Scopus)

Full list of publications: https://www.scopus.com/authid/detail.uri?authorId=55338397300

I hereby authorize the use of my personal data in accordance to the GDPR 679/16 - "European regulation on the protection of personal data".

Torino, 16/10/2022 Umberto Manera